Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma

PURPOSE: In the phase 3 CheckMate 9ER trial, intravenous nivolumab (240 mg every 2 weeks) plus oral cabozantinib (40 mg/day) improved progression-free survival (PFS) versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC). To support cabozantinib dosing with the combination, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Benjamin Duy, Li, Jing, Ly, Neang, Faggioni, Raffaella, Roskos, Lorin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905187/
https://www.ncbi.nlm.nih.gov/pubmed/36625894
http://dx.doi.org/10.1007/s00280-022-04500-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905187/
https://www.ncbi.nlm.nih.gov/pubmed/36625894
http://dx.doi.org/10.1007/s00280-022-04500-9

Ejemplares similares